Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study

View Full Paper
Ask AI
Bookmark
Share

Authors

QTQianshan Tao

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds targeted treatment improves outcomes in B-ALL patients post-CD19 CAR-T relapse, highlighting the importance of salvage therapy.

Key Points

  • Patients with relapsed B-ALL show improved overall survival with targeted therapy versus chemotherapy, suggesting clinical benefit.
  • Monoclonal antibodies and targeted treatment achieved higher complete remission rates compared to chemotherapy in this population.
  • A retrospective multi-institutional study highlighted salvage therapy's significance in addressing relapsed/refractory B-ALL.
  • Extramedullary disease with CNS involvement indicates better prognosis, demonstrating the need for specialized treatment approaches.

Cite This Study

Qianshan Tao (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4dahttps://doi.org/10.1182/blood-2025-6854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study2025 · 3 citations
  2. 2Targeting the sanctuary sites: Allogeneic CD19 CAR-T therapy for extramedullary relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation2025
  3. 3Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025
  4. 4Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy2025
  5. 5Outcomes with chimeric antigen receptor-t cell therapy in relapsed/refractory b-cell acute lymphoblastic leukemia: A systematic review and meta-analysis2025